- Previous close
145.21 - Open
143.19 - Bid --
- Ask --
- Day's range
142.30 - 144.44 - 52-week range
86.58 - 151.40 - Volume
1,089,054 - Avg. Volume
1,736,845 - Market cap (intra-day)
22.949B - Beta (5Y monthly) 1.15
- PE ratio (TTM)
-- - EPS (TTM)
-19.15 - Earnings date 7 Nov 2024 - 11 Nov 2024
- Forward dividend & yield --
- Ex-dividend date --
- 1y target est
156.41
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.
www.illumina.com10,590
Full-time employees
31 December
Fiscal year ends
Healthcare
Sector
Diagnostics & Research
Industry
Recent news: ILMN
View more
Performance overview: ILMN
Trailing total returns as of 22/10/2024, which may include dividends or other distributions. Benchmark is
.YTD return
1-year return
3-year return
5-year return
Compare to: ILMN
Select to analyse similar companies using key performance metrics; select up to four stocks.
Statistics: ILMN
View moreValuation measures
Market cap
23.13B
Enterprise value
25.06B
Trailing P/E
--
Forward P/E
32.79
PEG ratio (5-yr expected)
0.68
Price/sales (ttm)
5.20
Price/book (mrq)
16.11
Enterprise value/revenue
5.66
Enterprise value/EBITDA
--
Financial highlights
Profitability and income statement
Profit margin
-68.73%
Return on assets (ttm)
1.43%
Return on equity (ttm)
-76.19%
Revenue (ttm)
4.43B
Net income avi to common (ttm)
-3.04B
Diluted EPS (ttm)
-19.15
Balance sheet and cash flow
Total cash (mrq)
994M
Total debt/equity (mrq)
203.41%
Levered free cash flow (ttm)
859M